Please assess the completion status of the following clinical trial:

Trial Title: A Multiple Ascending Dose Study of Safety and Pharmacokinetics of NP10679 in Normal Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects aged 18 to 55 years~* Ability to understand the requirements of the study, provide written informed consent, abide by the study restrictions, and agree to return for the required assessments.~* If of child bearing potential (both men and women) must agree to use 2 forms of contraceptive methods for the duration of study.~Exclusion Criteria:~* Clinical laboratory values greater than or equal to 2 times the upper limit of normal.~* Recent history (within 2 yrs) or current tobacco use.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo intravenous infusion over 30 minutes, five days of once daily dosing
- NP10679 25 mg (Type: EXPERIMENTAL): NP10679 25 mg intravenous infusion over 30 minutes, five days of once daily dosing
- NP10679 50 mg (Type: EXPERIMENTAL): NP10679 50 mg intravenous infusion over 30 minutes, five days of once daily dosing
- NP10679 100 mg (Type: EXPERIMENTAL): NP10679 100 mg intravenous infusion over 30 minutes, five days of once daily dosing

Based on this trial design, predict the completion outcome and termination type (if applicable).